What is a common adverse effect of the BRAF inhibitors cobimetinib and trametinib?

BRAF inhibitors, such as cobimetinib and trametinib, primarily target the mitogen-activated protein kinase (MAPK) pathway, which is crucial in cell division and proliferation. A well-documented adverse effect associated with these medications is retinopathy, which can manifest as visual disturbances, blurred vision, or other visual changes. The occurrence of retinopathy is particularly relevant in patients receiving these targeted therapies, necessitating regular eye examinations and monitoring for any signs of visual impairment.

This side effect is linked to the modulation of the MAPK pathway that affects various tissues, including the retina. Understanding this link helps healthcare providers to be vigilant about the potential for retinopathy in patients undergoing treatment with these inhibitors.